Havana, Jan 6 (Prensa Latina) Cuba and Malaysia signed deal for the distribution in that country of Heberprot-P, a drug for the healing of complex wounds, ischemic ulcers and those resulting from diabetic foot, was announced here on Wednesday.
The deal was signed in the Malaysian nation by the company for the production and trade of innovative medicines Ubisson and the Center for Genetic Engineering and Biotechnology (CIGB), creator of the product, according to the latter on Twitter.
Such document was signed by Ubisson’s executive director, Peter Ting, and witnessed by the Cuban ambassador in Malaysia, Ibete Fernandez Hernandez.
In addition, they were attended by the Secretary General of the Ministry of Industry and Trade of that country, Dato Lokman Hakim Bin Ali, who advocated extending cooperation to introduce other highly effective Cuban biotechnology products into the Malaysian market.
Initially, the document was signed in Havana by Eulogio Pimentel, director of the CIGB, the largest institution of Cuba devoted to research, development, production and commercialization of products.
The deal is also protected by the National Institute of Diabetes of Malaysia and it is expected that its registration will be issued in that country previous the end of 2021.
Specialists assure that Heberprot-P increases the frequency of effective granulation formation in treated lesions and therefore, reduces the risks of amputation.